Literature has consistently reported a relationship between increased synthesis of HSP70 and MS, [9,10]—as MS lesions trigger inflammation and oxidative stress in the CNS, the expression of several HSP proteins including HSP70 increases, and this increased release of HSP70 is thought to promote the T-cell immune response by either acting as an adjuvant for myelin peptides or as a proinflammatory cytokine [10,11]. Here, HSP90B2P is linked to myeloid sarcoma.